Health Care Equipment

Treace Medical Concepts

Treace Medical Concepts released FY2026 Q1 earnings on May 8 Pre-Market EST, actual revenue USD 47.2 M (forecast USD 46.05 M), actual EPS USD -0.28 (forecast USD -0.3078)

Treace Medical Concepts to Release FY2026 Q1 Earnings on May 8 Pre-Market EST, Forecast Revenue USD 46.05M, EPS USD -0.3078

Treace Medical Concepts released FY2025 annual earnings on February 27 Pre-Market EST, actual revenue USD 212.69 M (forecast USD 212 M), actual EPS USD -0.9325 (forecast USD -0.9368)

Treace Medical Concepts released FY2025 Q4 earnings on February 27 Pre-Market (EST), actual revenue USD 62.52 M (forecast USD 61.87 M), actual EPS USD -0.1471 (forecast USD -0.1499)

Treace Medical Concepts to Release FY2025 Q4 Earnings on February 27, Pre-Market EST; Forecast Revenue USD 61.87 M, EPS USD -0.1499

Rick Wise Maintains Hold Rating on Treace Medical Concepts

Treace Medical Concepts released FY2025 Q3 earnings on November 6 After-Market EST, actual revenue USD 50.21 M (forecast USD 49.6 M), actual EPS USD -0.26 (forecast USD -0.2806)

Treace Medical Concepts released FY2025 9 Months Earnings on November 6 After-Market EST, actual revenue USD 150.17 M, actual EPS USD -0.7866

Treace Medical Concepts to Release FY2025 Q3 Earnings on November 6 After-Market (EST), Forecast Revenue USD 49.6 M, EPS USD -0.2806

Treace Medical Concepts released FY2025 Semi-Annual earnings on August 7 After-Market EST, with actual revenue of USD 99.96 M and EPS of USD -0.5302

Treace Medical Concepts released FY2025 Q2 earnings on August 7 After-Market EST, actual revenue USD 47.39 M (forecast USD 47.08 M), actual EPS USD -0.2761 (forecast USD -0.2886)

Treace Medical Concepts to Release FY2025 Q2 Earnings on August 7 After-Market (EST), Forecast Revenue USD 47.08M, EPS USD -0.2886

Treace Medical Gets Consensus Hold Ratings from Seven Firms

Treace Medical Concepts Sued for Securities Fraud

Treace Medical Sued for Securities Fraud in Class Action

Rosen Advises TMCI Stockholders of Important Date

Treace Medical Concepts Sues Zimmer Biomet and Paragon 28 for Patent Infringement

Faruqi & Faruqi Investigating Treace Medical Misleading Claims

Faruqi & Faruqi Initiates Securities Class Action on Behalf of Treace Medical Investors

Treace Medical Concepts Faces Securities Fraud Lawsuit

Freecast

Cuprina

U-BX Tech

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Defiance Pure Space Dly 2X Strat ETF

VS MEDIA

Everbright Digital

Park Ha Biological Tech

Friedman Industries

Defiance Daily Target 2X Short ASTS ETF

RNAZ

TMCI

CLOV

SCLX

GMRS

Top biotech gainers included Parabilis (PBLS), which surged 58% following its Nasdaq IPO debut, and Clover Health (CLOV), which rallied over 13% after winning a legal dispute with the HHS regarding its Medicare Star Rating. Other notable movers were Shoulder Innovations (SI) up 16% on strong revenue outlooks, Myomo (MYO) up 17%, Scilex (SCLX) up 25%, and GMR Solutions (GMRS) up 13%.

rttnews

Shoulder Innovations

TransCode Therapeutics

Clover Health Investments

Scilex

Myomo

GMR Solutions

Top Biotech Gainers: PBLS Soars Over 50%, CLOV Rallies On Legal Win, RNAZ, TMCI On Watch

Treace Medical Concepts CEO John T. Treace purchased 50,000 shares valued at $177,500 on June 1, 2026, signaling confidence in the company. This follows Q1 results showing revenue slightly above expectations but down year-over-year with widening losses. Despite strong gross margins and moderating cash burn, analysts maintain cautious targets due to negative free cash flow and flat-to-lower 2026 sales guidance. TipRanks' AI Analyst rates TMCI as Neutral.

Tip Ranks

CEO Makes Bold Insider Move at Treace Medical Concepts

CDNL

NDAQ

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

nasdaq

Cardinal Infrastructure

Nasdaq

Cardinal (CDNL) Q1 2026 Earnings Transcript

Insider buying at Treace Medical Concepts (TMCI) by CEO John T. Treace, who purchased 115,520 shares for $339,704, indicates growing confidence in the company's prospects. Despite reaffirming 2026 revenue guidance, analysts remain neutral due to ongoing losses and negative cash flow. TMCI's stock has seen mixed fundamentals, with a current market cap of $183.6M and a year-to-date price performance of 18.37%. Technical signals suggest a sell, reflecting concerns over financial performance and a cautious outlook.

SPDR S&P Health Equip

iShares US Medical Devices

Major Insider Buy Signals Growing Confidence at Treace Medical Concepts

At Treace Medical's annual meeting, shareholders elected directors for three-year terms, approved executive compensation, and ratified Grant Thornton as auditors for 2026. The board's structure received strong support, indicating confidence in the company's strategy. Analysts rate TMCI stock as a Hold with a $2.00 target, citing weak financial performance despite strong gross margins. The company focuses on surgical solutions for foot and ankle conditions.

Treace Medical Shareholders Back Directors, Pay and Auditor

Treace Medical Concepts shares are trading higher after the company reported better-than-expected Q1 financial results and raised. its FY26 sales guidance.

benzinga_article